secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001628280-25-038094
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027
--------------------------------------------------------------------------------

- Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.
- Patient 1 maintained ~50% HBsAg reduction 7 months after initial dose, indicating durable antiviral editing.
- Cohort 2 (0.4 mg/kg) shows no Grade 3+ AEs; DMC approved escalation to Cohort 3.
- Cash runway extended to H2 2027 via ~$25M annual operating expense reduction program starting July 2025.
- Dr. Mark Sulkowski appointed Head Clinical Development Advisor for PBGENE-HBV and later-stage trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828025038094/0001628280-25-038094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828025038094/dtil-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer